HLA
PACB icon

Hamilton Lane Advisors’s Pacific Biosciences PACB Stock Holding History

Hamilton Lane Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,091
Closed -$288K – 88
2021
Q4 		$288K Hold
14,091
– – 0.04% 79
2021
Q3 		$360K Hold
14,091
– – 0.06% 64
2021
Q2 		$493K Hold
14,091
– – 0.15% 59
2021
Q1 		$469K Buy
+14,091
New +$493K 0.15% 56

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Hamilton Lane Advisors's PACB Position: Q1 2022 in Review

Hamilton Lane Advisors sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 14,091 shares — an estimated $288K sold.

Hamilton Lane Advisors first reported a position in PACB in Q1 2021 and held it in 4 quarters. The position peaked at $493K in Q2 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • Hamilton Lane Advisors reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 14,091 Pacific Biosciences shares in Q1 2022, an estimated $288K.
  • Hamilton Lane Advisors first reported a position in Pacific Biosciences in Q1 2021 and held it in 4 quarters.
  • Hamilton Lane Advisors's Pacific Biosciences position peaked at $493K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Hamilton Lane Advisors's 13F filing for Q1 2022, filed 4 May 2022.